ГоловнаArchive of numbers2016Volume 24, issue 1 (86)Modern views on etiopathogenesis, diagnostics and treatment of neuromyelitis optica (Devic’s disease)
Title of the article Modern views on etiopathogenesis, diagnostics and treatment of neuromyelitis optica (Devic’s disease)
Authors Mialovytska Olena
Kobys T.
Khyzhnyak A. A.
In the section PROBLEMATIC AND REVIEW ARTICLES
Year 2016 Issue Volume 24, issue 1 (86) Pages 11-16
Type of article Scientific article Index UDK 616.831/832-018.834-007.232-02-092-07 Index BBK -
Abstract The article deals with neuromyelitis optica (Devic’s disease) — idiopathic, immune-mediated demyelinating disease of the central nervous system that belongs to autoimmune channelopathies and has humoralmediated mechanism of development. The article presents modern data on etiopathogenesis, diagnostic criteria and diff erential diagnosis of neuromyelitis optica. Modern diagnostic criteria help to set an accurate diagnosis with presence of optic neuritis and myelitis clinical manifestations. The article also provides main principles of neuromyelitis optica therapy: treatment of aggravations, preventive therapy aimed at stabilization of demyelinating process and methods of symptomatic therapy.
Key words neuromyelitis optica, aquaporins, preventive therapy
Access to full text version of the article pdf download
Bibliography 1. Оптикомиелит Девика: вопросы диагностики и описание случая из практики / [Шахов Б. Е., Белова А. Н., Шаленков И. В., Шакурова Д. Н.] // Медицинский альманах. — 2012. — № 1 (20). — С. 165—170. 2. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis opticaimmunoglobulin / [Asavapanumas N., Ratelade J., Papadopoulos M. C. et al.] // G. J. Neuroinflammation. — 2014. — № 11. — Р. 16. 3. Bakker J. Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG) / J. Bakker, L. Metz // Can J Neurol Sci. — 2004. — № 31. — Р. 265—267. 4. Immunoglobulins and complement in postmortem multiple sclerosis tissue / [Barnett M. H., Parratt J. D., Cho E. S., Prineas J. W.] // Ann. Neurol. — 2009. — № 65 (1). — P. 32—46. 5. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients / [Bichuetti D. B., Oliveira E. M., de Boulos F. C., Gabbai A. A.] // Arch Neurol. — 2012. — № 69. — Р. 938—939. 6. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution / [Bizzoco E., Lolli F., Repice A. M. et al.] // J. Neurol. — 2009. — № 256. — P. 1891—1898. 7. Bukhari W. Molecular Pathogenesis of Neuromyelitis Optica / Bukhari W., Barnett H. M., Prain K. // J. Mol. Sci. — 2012. — № 13. — Р. 12970—12993. 8. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica / [Chihara N., Aranami T., Sato W. et al.] // Proc Natl Acad Sci USA. — 2011. — № 108. — Р. 3701—3706. 9. Azathioprine: tolerability, efficacy and predictors of benefit in neuromyelitis optica / [Costanzi C., Matiello M., Lucchinetti C. F. et al.] // Neurology. — 2011. — № 77. — Р. 659—666. 10. Davies A. Membrane defence against complement lysis: the structure and biological properties of CD59 / A. Davies, P. J. Lachmann // Immunol Res. — 1993. — № 12. — 258—275. 11. Fagius J. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation / Fagius J., Lundgren J., Oberg G. // Mult Scler. — 2008. — № 15. — Р. 229—237. 12. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? / [Higgs J. E., Payne K., Roberts C., Newman W. G.] // Pharma cogenomics. — 2010. — № 11. — 177—188. 13. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus / [Illei G. G., Cervera R., Burt R. K. et al.] // Ann Rheum Dis. — 2011. — № 70. — Р. 2071—2074. 14. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis / [Iwata K., Doi A., Ohji G. et al.] // Intern Med. — 2010. — № 49. — Р. 2423—2432. 15. A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment [Japanese] / [Izaki S., Narukawa S., Kubota A. et al.] // Rinsho Shinkeigaku. — 2013. — № 53. — Р. 513—517. 16. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence / [Jacob A., Saadoun S., Kitley J. et al.] // Mult Scler. — 2012. — № 18. — Р. 1801—1803. 17. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients / [Jacob A., Matiello M., Weinshenker B. G. et al.] // Arch Neurol. — 2009. — № 66. — Р. 1128—1133. 18. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients / [Jacob A., Weinshenker B. G., Violich I. et al.] // Ibid. — 2008. — № 65. — Р. 1443—1448. 19. The epidemiology of neuromyelitis optica among adults in the Merseyside county of United Kingdom / [Jacob A., Panicker J., Lythgoe D., Elsone L. et al.] // J. Neurol. — 2013. — № 260. — P. 2134—2137.20. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures / [Jarius S., Paul F., Franciotta D. et al.] // J Neurol Sci. — 2011. — № 306. — Р. 82—90. 21. Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4 / [Jarius S., Jacob S., Waters P. et al.] // J Neurol Neurosurg Psychiatr. — 2008. — № 79. — P. 1084. 22. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica; a multicentre study of 175 patients/ [Jarius S., Ruprecht K., Wildemann B. et al.] // J Neuroinflammation. — 2012. — № 9. — P. 14. 23. NMO-Ig G positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy/ [Kay C. S. K., Scola R. H., Lorenzoni P. J. et al.] // J. Neurol. Sci. — 2008. — № 275. — P. 148—150. 24. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica/ [Kim S. H., Kim W., Park M. S. et al.] // Arch Neurol. — 2010. — № 68. — Р. 473—479. 25. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years/ [Kim S-H., Kim W., Li X. F. et al.] // Ibid. — 2011. — № 68. — Р.1412—1420. 26. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies/ [Kitley J., Leite M. I., Küker W. et al.] // JAMA Neurol. — 2013. — № 70. — Р. 1375—1381. 27. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies / [Kitley J., Elsone L., George J. et al. ] // J Neurol Neurosurg Psychiatry. — 2013. — № 84. — Р. 918—921. 28. Failure of natalizumab to prevent relapses in neuromyelitis optica / [Kleiter I., Hellwig K., Berthele A. et al.] // Arch Neurol. — 2012. — № 69. — Р. 239—245. 29. Lewis L. A. Meningococcal disease and the complement system / L. A. Lewis, S. Ram // Virulence. — 2014. — № 5. — Р. 98—126. 30. Spectrum of pediatric neuromyelitis optica / [Lotze T. E., Northrop J. L., Hutton G. J. et al.] // Pediatrics. — 2008. — № 122. — P. 1039—1047. 31. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica / [Lucchinetti C. F., Mandler R. N., McGavern D. et al.] // Brain. — 2002. — № 125. — Р. 1450—1461. 32. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders / [Mader S., Gredler V., Schanda K. et al.] // J Neuroinflammation. — 2011. — № 8. — Р. 184. 33. Magraner M. J. The effect of intravenous immunoglobulin on neuromyelitis optica / Magraner M. J., Coret F., Casanova B. // Neurologia. — 2012. — № 28. — Р.65—72. 34. Min J. H. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder / Min J. H., Kim B. J., Lee K. H. // Mult Scler. — 2012. — № 18. — Р. 113—115. 35. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation / [Neff R. T., Hurst F. P., Falta E. M. et al.] // Transplantation. — 2008. — № 86. — Р. 1474—1478. 36. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers / [Palace J., Leite M. I., Nairne A., Vincent A.] // Arch Neurol. — 2010. — № 67. — Р. 1016—101. 37. Parratt J. D. Neuromyelitis optica: f demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes / J. D. Parratt, J. W. Prineas // Mult. Scler. — 2010. — № 16. — P. 1156—1172. 38. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab / [Pellkofer H. L., Krumbholz M., Berthele A. et al.] // Neurology. — 2011. — № 76. — Р.1310—1315. 39. TNF-α and IL-10 downregulation and marked oxidative stress in neuromyelitis optica / [Pentón-Rol G., Cervantes-Llanos M., Martínez-Sánchez Gr. et al.] // Journal of Inflammation (Lond). — 2009. — № 6. — Р. 18. 40. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays / [Phuan P. W., Ratelade J., Rossi A. et al.] // J Biol Chem. — 2012. — № 287. — Р. 13829—13839. 41. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study / [Pittock S. J., Lennon V. A., McKeon A. et al.] // Lancet Neurol. — 2013. — № 12. — Р. 554—562. 42. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis / [Polman C. H, O’Connor P. W., Havrdova E. et al.] // N Engl J Med. — 2006. — № 354. — Р. 899—910. 43. Ricklin D. Complement-targeted therapeutics / D. Ricklin, J. D. Lambris // Nat Biotechnol. — 2007. — № 25. — Р. 1265—1275. 44. Neutrophil protease inhibition reduces neuromyelitis opticaimmunoglobulin G-induced damage in mouse brain / [Saadoun S., Waters P., MacDonald C. et al.] // Ann Neurol. — 2012. — № 71. — Р. 323—333. 45. EFNS guidelines on diagnosis and management of neuromielitis optica / [Seller J., Djggild M., Clanet M et al.] // European Journal of Neurology. — 2010. — № 17. — P. 1019—1032. 46. Sera from neuromyelitis optica patients disrupt the bloodbrain barrier / [Shimizu F., Sano Y., Takahashi T. et al.] // J Neurol Neurosurg Psychiatry. — 2012. — № 83. — Р. 288—297. 47. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum / [Shimizu J., Hatanaka Y., Hasegawa M. et al.] // Neurology. — 2010. — № 75. — Р. 1423—1427. 48. Sofroniew M.V. Astrocytes: Biology and pathology / M. V. Sofroniew, H. V. Vinters // Acta Neuropatholog. — 2010. — № 119. — P. 7—35. 49. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica / [Tradtrantip L., Zhang H., Saadoun S. et al.] // Ann Neurol. — 2012. — № 71. — Р. 314—322. 50. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G. into therapeutic antibody / [Tradtrantip L., Ratelade J., Zhang H., Verkman A. S.] // Ibid. — 2013. — № 73. — Р. 77—85. 51. Trebst C. Update on the diagnosis and treatment of neuromye litis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) / Trebst C., Jarius S., Berthele A. // J. of Neurol. — 2014. — № 26 (1). — Р. 1—16. 52. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks / [Uzawa A., Mori M., Sawai S. et al.] // Clin Chim Acta. — 2013. — № 421. — Р. 181—183. 53. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population / [Vaknin- Dembinsky A., Orpaz N., Abramsky O., Karussis D.] // Mult. Scler. — 2010. — № 16. — P. 1453—1457. 54. Verkman A. S. More than just water channels: unexpected cellular roles of aquaporins / A. S. Verkman // J. Cell Sci. — 2005. — № 118. — P. 3225—3232. 55. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren’s syndrome / [Wandinger K-P., Stangel M., Witte T. et al.] // Arthritis Reum. — 2010. — № 62. — P. 1198—1200. 56. The spectrum of neuromyelitis optica / [Wingerhuk D. M., Lennon V. A., Luhinetti C. F., Pittock S. J.] // Lancet Neurol. — 2007. — № 6. — P. 805—815. 57. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder / [Yaguchi H., Sakushima K., Takahashi I. et al.] // Intern Med. — 2013. — № 52. — Р. 969—972. 58. Zhang H. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopatogenic mechanisms / Zhang H., Bennett J. L., Verkman A. S. // Ann. Neurol. — 2011. — № 70. — P. 943—954. 59. Zhang H. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica / H. Zhang, A. S. Verkman // J Clin Invest. — 2013. — № 123. — Р. 2306—2316.